Detalhe da pesquisa
1.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Lancet Oncol
; 24(7): 772-782, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37276871
2.
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Future Oncol
; 18(29): 3255-3266, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000541
3.
Admixture mapping implicates 13q33.3 as ancestry-of-origin locus for Alzheimer disease in Hispanic and Latino populations.
HGG Adv
; 4(3): 100207, 2023 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37333771